Gain insight on how industry thinks about a dry eye opportunity, or a cross-linking opportunity, or a uveitis opportunity. The discussion is about no so much what they liked and didn’t like about the earlier presentations at OIS@ASCRS, but in general, what does a company have to do to get their attention, take a deeper look, and maybe even do a partnership or a deal.
Emmett T. Cunningham Jr., MD, PhD, MPH
Dr. Cunningham joined Clarus Ventures with 20+ years in the biomedical and biopharmaceutical sectors. Prior, Dr. Cunningham was the SVP, Medical Strategy at Eyetech Pharmaceuticals.
Laurent Attias is Senior Vice President, Head of Strategy, BD&L and M&A. In this role, Mr. Attias leads the development of Alcon’s long-term strategic plan.
Quinton Oswald is the CEO of Neurotech. Prior to joining Neurotech, he served as the CEO of SARcode Bioscience, a San Francisco-based biotech that developed lifitegrast, an investigational product for dry eye disease.
Calvin W. Roberts, MD
Calvin W. Roberts, MD, is Executive Vice President and the Chief Medical Officer at Bausch + Lomb. A specialist in cataract and refractive surgery, Dr. Roberts is credited with developing surgical therapies, over-the-counter products for vision care, prescription ocular therapeutics, and innovative treatment regimens.
Jane E. Rady
Jane Rady is DVP, Business Development for AMO. She joined AMO in 2002 as a corporate officer serving in various capacities.